American Journal of Epidemiology Vol. 135, No. 2: 190-199
Copyright © 1992 by The Johns Hopkins University School of Hygiene and Public Health
research-article |
The LiFraumeni Syndrome: From Clinical Epidemiology to Molecular Genetics
1Department of Experimental Pediatrics, The University of Texas M. D. Anderson Cancer Center Houston, TX.
3Department of Tumor Biology, The University of Texas M. D. Anderson Cancer Center Houston, TX.
Reprint requests to Dr. Louise C. Strong, Experimental Pediatrics/Genetics, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd , HMB Box 209, Houston, TX 77030.
The goal of this review is to demonstrate the effective interaction of epidemiologic methods and molecular genetics in the identification of familial cancer predisposition. The example involves a hospitalbased population of childhood soft tissue sarcoma patients who were less than age 16 years at diagnosis at the University of Texas M. D. Anderson Cancer Center, Houston, Texas, in 1944 through 1976, had survived at least 3 years from diagnosis, and were diagnosed at least 5 years before the start of our study. Familial data were collected on the patients' offspring, full siblings, parents, aunts, uncles, and grandparents. The initial analysis revealed a small but significant cancer excess in firstdegree relatives. Genetic analysis demonstrated that the cancer distribution in families could best be explained by a rare autosomal dominant gene with penetrance such that the risk of cancer by age 35 years was nearly 50% Most of the evidence for a dominant gene came from nine kindreds. Laboratory investigation of fibroblasts from those kindreds provided an in vitro model of cellular immortalization and carcinogenesis. Germline mutations in the tumor suppressor gene p53 were found in two of the families, and studies are ongoing in the other kindreds. This review demonstrates the power of genetic epidemiologic methods to characterize statistically a cancerpredisposing gene and the application of molecular genetics to define the genetic defect. Am J Epidemiol 1992;135:1909.
genes; mutation; sarcoma
2Deceased.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
C.-C. Wu, S. Shete, C. I. Amos, and L. C. Strong Joint Effects of Germ-Line p53 Mutation and Sex on Cancer Risk in Li-Fraumeni Syndrome Cancer Res., August 15, 2006; 66(16): 8287 - 8292. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Clark, C. Fisher, I. Judson, and J. M. Thomas Soft-Tissue Sarcomas in Adults N. Engl. J. Med., August 18, 2005; 353(7): 701 - 711. [Full Text] [PDF] |
||||
![]() |
K. E. Nichols, S. Levitz, K. E. Shannon, D. C.R. Wahrer, D. W. Bell, G. Chang, S. Hegde, D. Neuberg, T. Shafman, N. J. Tarbell, et al. Heterozygous Germline ATM Mutations Do Not Contribute to Radiation-Associated Malignancies After Hodgkin's Disease J. Clin. Oncol., April 1, 1999; 17(4): 1259 - 1259. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. B. Halberg, D. S. Katzung, P. D. Hoff, A. R. Moser, C. E. Cole, R. A. Lubet, L. A. Donehower, R. F. Jacoby, and W. F. Dove Tumorigenesis in the multiple intestinal neoplasia mouse: Redundancy of negative regulators and specificity of modifiers PNAS, March 28, 2000; 97(7): 3461 - 3466. [Abstract] [Full Text] [PDF] |
||||



